<p>在 Google 搜索和 AI 答案中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开 Google</p>
<p>在 Google 上添加</p>
<p>以色列佩塔赫提克瓦，2026 年 6 月 11 日（全球新闻稿）——NANO-X IMAGING LTD（“Nanox” 或 “公司”，纳斯达克代码：NNOX），一家创新的医疗成像技术公司，今天宣布将于 2026 年 6 月 25 日星期四市场开盘前公布截至 2026 年 3 月 31 日的季度财务业绩。首席执行官兼代理董事长 Erez Meltzer 和首席财务官 Ran Daniel 将主持电话会议，回顾这些业绩并提供业务更新，会议将于东部时间上午 8:30 开始。</p>
<p>感兴趣的各方可以使用以下链接注册电话会议：Nanox 2026 年第一季度电话会议注册</p>
<p>电话会议的直播网络广播可以通过以下链接访问 <strong>:</strong> Nanox 2026 年第一季度网络广播</p>
<p>网络广播链接也将在 Nanox 网站的投资者关系部分的活动和演示中发布。</p>
<p><strong>关于 Nanox</strong></p>
<p>Nanox（纳斯达克：NNOX）专注于通过提供集成的端到端医疗成像和医疗服务平台，推动全球向预防性医疗保健的转型。</p>
<p>Nanox 结合了经济实惠的成像硬件、先进的基于 AI 的解决方案、基于云的软件、远程放射学的访问、健康 IT 解决方案以及一个市场，以实现更早的疾病检测、提高临床效率和更广泛的医疗服务获取。</p>
<p>Nanox 的愿景是通过提供从扫描到解读及更远的无缝解决方案，扩大医疗成像在传统医院环境内外的覆盖范围。通过利用专有的数字 X 射线技术、基于 AI 的分析和临床驱动的方法，Nanox 旨在提高常规成像工作流程的效率，支持早期疾病检测，并改善患者结果。</p>
<p>Nanox 生态系统包括 Nanox.ARC，一种经济高效、易于使用和可扩展的 3D 多源数字断层合成成像系统；Nanox.AI，一套基于 AI 的算法，增强常规 CT 成像的解读，以识别与慢性疾病相关的早期迹象；Nanox.CLOUD，一个用于安全数据管理、存储和先进成像分析的云平台；Nanox.MARKETPLACE 和 USARAD Holdings，提供远程放射学和心脏病学专家的访问以及全面的远程放射学服务；以及 Nanox Health IT，结合深厚的医疗 IT 专业知识与领先技术合作伙伴，提供 RIS、PACS、AI、听写和安全基础设施解决方案，以简化工作流程并支持更安全、更高效的医疗服务交付。</p>
<p>通过整合成像技术、AI、云基础设施、临床专业知识、市场和健康信息技术，Nanox 力求降低采用障碍，提高利用率，并推动全球预防性医疗的发展。有关更多信息，请访问 www.nanox.vision</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿可能包含前瞻性声明，这些声明受到风险和不确定性的影响。本新闻稿中所有非历史事实的声明均为前瞻性声明。这些声明包括但不限于与公司在其 X 射线源技术和 Nanox.ARC 方面的研究与开发、制造和商业化活动的启动、时间、进展和结果相关的任何声明，以及实现其近期收购的预期收益和公司及被收购公司的预期商业前景。在某些情况下，您可以通过诸如 “可以”、“可能”、“相信”、“可能”、“估计”、“继续”、“预期”、“打算”、“应该”、“计划”、“能够”、“期待”、“预测”、“潜在” 或这些术语的否定形式或其他类似表达来识别前瞻性声明。前瞻性声明基于公司在作出这些声明时所掌握的信息或管理层在当时对未来事件的善意信念，并且受到风险和不确定性的影响，这可能导致实际表现或结果与前瞻性声明中表达或暗示的内容有实质性差异。可能导致实际结果与当前预期有实质性差异的因素包括：(i) Nanox 完成 Nanox 系统开发的能力；(ii) Nanox 成功展示其技术在商业应用中可行性的能力；(iii) Nanox 历史上持续亏损和经营活动负现金流的情况、未来重大承诺以及对 Nanox 流动性是否足以追求其完整商业目标的不确定性，以及对其持续经营能力的重大怀疑；(iv) Nanox 对其技术、Nanox.ARC 和 Nanox.CLOUD 在全球监管机构的监管许可或批准的必要性、申请时间和获得及维持的预期；(v) Nanox 实现收购预期收益的能力，这可能受到竞争、品牌认知度、被收购公司盈利增长和管理增长的能力以及留住关键员工等因素的影响；(vi) Nanox 与第三方制造商和供应商达成并维持商业合理安排以制造 Nanox.ARC 的能力；(vii) Nanox 系统及其拟议的按扫描付费商业模式的市场接受度；(viii) Nanox 对与第三方合作及其潜在收益的预期；(ix) Nanox 在全球范围内开展业务的能力；(x) 全球、政治、经济、商业、竞争、市场和监管力量的变化；(xi) 与以色列和哈马斯之间当前战争相关的风险以及以色列局势的任何恶化；(xii) 与 COVID-19 大流行或类似公共卫生危机相关的业务中断风险；以及 (xiii) 与我们交易相关的潜在诉讼。</p>
<p>有关其他风险和不确定性以及其他重要因素的讨论，任何这些因素都可能导致 Nanox 的实际结果与前瞻性声明中包含的结果不同，请参见 Nanox 截至 2025 年 12 月 31 日的 20-F 表格年度报告中的 “风险因素” 部分，以及随后向美国证券交易委员会提交的文件。读者不应对本新闻稿中包含的任何前瞻性声明过于依赖。除法律要求外，Nanox 没有义务在本新闻稿日期之后公开更新任何前瞻性声明，以使这些声明与实际结果或公司预期的变化相符。</p>
<p><strong>联系方式</strong></p>
<p><strong>投资者联系</strong></p>
<p>Mike Cavanaugh</p>
<p>ICR Healthcare</p>
<p>mike.cavanaugh@icrhealthcare.com</p>
<p><strong>媒体联系</strong></p>
<p>ICR Healthcare</p>
<p>NanoxPR@icrinc.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjek5URTNOaU0zTmpVMk16STNJekl4T1RVeU5UWT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjek5URTNOaU0zTmpVMk16STNJekl4T1RVeU5UWT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzliZmE2NzctYWFmZC00ZjZlLTllODgtODkyNmY5YzlmNDJhLTEyMDY4MDktMjAyNi0wNi0xMS1lbg==/tiny/Nano-X-Imaging-Ltd.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzliZmE2NzctYWFmZC00ZjZlLTllODgtODkyNmY5YzlmNDJhLTEyMDY4MDktMjAyNi0wNi0xMS1lbg==/tiny/Nano-X-Imaging-Ltd.png"/></p>

NNOX

<p>Nanox Imaging（纳斯达克股票代码：NNOX）宣布将于 2026 年 6 月 25 日市场开盘前公布其 2026 年第一季度财务业绩。首席执行官 Erez Meltzer 和首席财务官 Ran Daniel 将于东部时间上午 8:30 召开电话会议，回顾业绩并提供业务更新。感兴趣的各方可以通过新闻稿中提供的链接注册参加电话会议或访问直播网络广播</p>

<p>See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google</p>
<div class="lb-trans"><p>在 Google 搜索和 AI 答案中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开 Google</p>
</div><p>Add on Google</p>
<div class="lb-trans"><p>在 Google 上添加</p>
</div><p>PETACH TIKVA, Israel, June 11, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (&#34;Nanox&#34; or the &#34;Company&#34;, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2026, before market open on Thursday, June 25, 2026. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.</p>
<div class="lb-trans"><p>以色列佩塔赫提克瓦，2026 年 6 月 11 日（全球新闻稿）——NANO-X IMAGING LTD（“Nanox” 或 “公司”，纳斯达克代码：NNOX），一家创新的医疗成像技术公司，今天宣布将于 2026 年 6 月 25 日星期四市场开盘前公布截至 2026 年 3 月 31 日的季度财务业绩。首席执行官兼代理董事长 Erez Meltzer 和首席财务官 Ran Daniel 将主持电话会议，回顾这些业绩并提供业务更新，会议将于东部时间上午 8:30 开始。</p>
</div><p>Interested parties may register for the conference call using the following link: Nanox Q1 2026 Call Registration</p>
<div class="lb-trans"><p>感兴趣的各方可以使用以下链接注册电话会议：Nanox 2026 年第一季度电话会议注册</p>
</div><p>The live webcast of the conference call may be accessed by using the following link <strong>:</strong> Nanox Q1 2026 Webcast</p>
<div class="lb-trans"><p>电话会议的直播网络广播可以通过以下链接访问 <strong>:</strong> Nanox 2026 年第一季度网络广播</p>
</div><p>The webcast link will also be posted in the Investor Relations section of the Nanox website at Events and Presentations.</p>
<div class="lb-trans"><p>网络广播链接也将在 Nanox 网站的投资者关系部分的活动和演示中发布。</p>
</div><p><strong>About Nanox</strong></p>
<div class="lb-trans"><p><strong>关于 Nanox</strong></p>
</div><p>Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.</p>
<div class="lb-trans"><p>Nanox（纳斯达克：NNOX）专注于通过提供集成的端到端医疗成像和医疗服务平台，推动全球向预防性医疗保健的转型。</p>
</div><p>Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.</p>
<div class="lb-trans"><p>Nanox 结合了经济实惠的成像硬件、先进的基于 AI 的解决方案、基于云的软件、远程放射学的访问、健康 IT 解决方案以及一个市场，以实现更早的疾病检测、提高临床效率和更广泛的医疗服务获取。</p>
</div><p>Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.</p>
<div class="lb-trans"><p>Nanox 的愿景是通过提供从扫描到解读及更远的无缝解决方案，扩大医疗成像在传统医院环境内外的覆盖范围。通过利用专有的数字 X 射线技术、基于 AI 的分析和临床驱动的方法，Nanox 旨在提高常规成像工作流程的效率，支持早期疾病检测，并改善患者结果。</p>
</div><p>The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.</p>
<div class="lb-trans"><p>Nanox 生态系统包括 Nanox.ARC，一种经济高效、易于使用和可扩展的 3D 多源数字断层合成成像系统；Nanox.AI，一套基于 AI 的算法，增强常规 CT 成像的解读，以识别与慢性疾病相关的早期迹象；Nanox.CLOUD，一个用于安全数据管理、存储和先进成像分析的云平台；Nanox.MARKETPLACE 和 USARAD Holdings，提供远程放射学和心脏病学专家的访问以及全面的远程放射学服务；以及 Nanox Health IT，结合深厚的医疗 IT 专业知识与领先技术合作伙伴，提供 RIS、PACS、AI、听写和安全基础设施解决方案，以简化工作流程并支持更安全、更高效的医疗服务交付。</p>
</div><p>By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit www.nanox.vision</p>
<div class="lb-trans"><p>通过整合成像技术、AI、云基础设施、临床专业知识、市场和健康信息技术，Nanox 力求降低采用障碍，提高利用率，并推动全球预防性医疗的发展。有关更多信息，请访问 www.nanox.vision</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of Nanox’s liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; (iv) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (v) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (vi) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vii) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (viii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (ix) Nanox’s ability to conduct business globally; (x) changes in global, political, economic, business, competitive, market and regulatory forces; (xi) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xii) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xiii) potential litigation associated with our transactions.</p>
<div class="lb-trans"><p>本新闻稿可能包含前瞻性声明，这些声明受到风险和不确定性的影响。本新闻稿中所有非历史事实的声明均为前瞻性声明。这些声明包括但不限于与公司在其 X 射线源技术和 Nanox.ARC 方面的研究与开发、制造和商业化活动的启动、时间、进展和结果相关的任何声明，以及实现其近期收购的预期收益和公司及被收购公司的预期商业前景。在某些情况下，您可以通过诸如 “可以”、“可能”、“相信”、“可能”、“估计”、“继续”、“预期”、“打算”、“应该”、“计划”、“能够”、“期待”、“预测”、“潜在” 或这些术语的否定形式或其他类似表达来识别前瞻性声明。前瞻性声明基于公司在作出这些声明时所掌握的信息或管理层在当时对未来事件的善意信念，并且受到风险和不确定性的影响，这可能导致实际表现或结果与前瞻性声明中表达或暗示的内容有实质性差异。可能导致实际结果与当前预期有实质性差异的因素包括：(i) Nanox 完成 Nanox 系统开发的能力；(ii) Nanox 成功展示其技术在商业应用中可行性的能力；(iii) Nanox 历史上持续亏损和经营活动负现金流的情况、未来重大承诺以及对 Nanox 流动性是否足以追求其完整商业目标的不确定性，以及对其持续经营能力的重大怀疑；(iv) Nanox 对其技术、Nanox.ARC 和 Nanox.CLOUD 在全球监管机构的监管许可或批准的必要性、申请时间和获得及维持的预期；(v) Nanox 实现收购预期收益的能力，这可能受到竞争、品牌认知度、被收购公司盈利增长和管理增长的能力以及留住关键员工等因素的影响；(vi) Nanox 与第三方制造商和供应商达成并维持商业合理安排以制造 Nanox.ARC 的能力；(vii) Nanox 系统及其拟议的按扫描付费商业模式的市场接受度；(viii) Nanox 对与第三方合作及其潜在收益的预期；(ix) Nanox 在全球范围内开展业务的能力；(x) 全球、政治、经济、商业、竞争、市场和监管力量的变化；(xi) 与以色列和哈马斯之间当前战争相关的风险以及以色列局势的任何恶化；(xii) 与 COVID-19 大流行或类似公共卫生危机相关的业务中断风险；以及 (xiii) 与我们交易相关的潜在诉讼。</p>
</div><p>For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.</p>
<div class="lb-trans"><p>有关其他风险和不确定性以及其他重要因素的讨论，任何这些因素都可能导致 Nanox 的实际结果与前瞻性声明中包含的结果不同，请参见 Nanox 截至 2025 年 12 月 31 日的 20-F 表格年度报告中的 “风险因素” 部分，以及随后向美国证券交易委员会提交的文件。读者不应对本新闻稿中包含的任何前瞻性声明过于依赖。除法律要求外，Nanox 没有义务在本新闻稿日期之后公开更新任何前瞻性声明，以使这些声明与实际结果或公司预期的变化相符。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投资者联系</strong></p>
</div><p>Mike Cavanaugh</p>
<div class="lb-trans"><p>Mike Cavanaugh</p>
</div><p>ICR Healthcare</p>
<div class="lb-trans"><p>ICR Healthcare</p>
</div><p>mike.cavanaugh@icrhealthcare.com</p>
<div class="lb-trans"><p>mike.cavanaugh@icrhealthcare.com</p>
</div><p><strong>Media Contact</strong></p>
<div class="lb-trans"><p><strong>媒体联系</strong></p>
</div><p>ICR Healthcare</p>
<div class="lb-trans"><p>ICR Healthcare</p>
</div><p>NanoxPR@icrinc.com</p>
<div class="lb-trans"><p>NanoxPR@icrinc.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjek5URTNOaU0zTmpVMk16STNJekl4T1RVeU5UWT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTczNTE3NiM3NjU2MzI3IzIxOTUyNTY="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzliZmE2NzctYWFmZC00ZjZlLTllODgtODkyNmY5YzlmNDJhLTEyMDY4MDktMjAyNi0wNi0xMS1lbg==/tiny/Nano-X-Imaging-Ltd.png" alt="" original-src="https://ml.globenewswire.com/media/MzliZmE2NzctYWFmZC00ZjZlLTllODgtODkyNmY5YzlmNDJhLTEyMDY4MDktMjAyNi0wNi0xMS1lbg==/tiny/Nano-X-Imaging-Ltd.png"/></p>

Nano-X Imaging 将于2026年6月25日公布 2026 年第一季度的财务业绩 | NNOX 股票新闻